CLINICAL_TRIALS
trial_result
· 2013-01-31
Clinical Trial Update: A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration [Phase 2]
Summary
Phase 2 results report safety and immunogenicity of repeated administration of recombinant human C1 esterase inhibitor in hereditary angioedema.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pharming Technologies B.V. | Conditions: Genetic Disorders, Hereditary Angioedema | Phase 2 | Status: COMPLETED | Results posted: 2013-01-31